The Real Reason Most Startups Fail at Go-To-Market (It's Not the Product)

It's Almost Never the Product

I've spent the better part of three decades watching startups make the same expensive mistake. Growth stalls, the board gets anxious, and the founder's first instinct is to look at the product roadmap. More features. A cleaner UI. Another integration the sales team swore would close three stuck deals. Another sprint cycle burns, another quarter passes, and the numbers still don't move.

Having served as CRO at companies like Scoro and Decile — and having built and sold VoyagerMed, and now running HedgeNova as CEO — I can tell you with real conviction: the product is almost never the problem. Go-to-market failure is a strategic and operational failure, not an engineering one. And until founders are willing to sit with that uncomfortable truth, they'll keep funding the wrong solutions.

The hardest thing to tell a technical founder isn't that their product needs work. It's that the product is fine — and the real problem is everything surrounding it.

The Pattern I See Repeatedly

Across the companies I've built, scaled, and advised, GTM dysfunction tends to cluster around four recurring failures. They look different on the surface, but they share a common root: a lack of disciplined focus.

1. No Clear Ideal Customer Profile

Most early-stage startups chase every inbound lead. It feels like momentum. It isn't. When you haven't made a hard decision about exactly who your product is built for — industry, company size, role, pain intensity, buying authority — your messaging becomes generic, your sales cycle lengthens, and your team spends energy on prospects that were never going to convert.

At Decile, one of the most important early exercises was forcing real specificity around the ICP. Not "mid-market e-commerce brands" — that's a category, not a customer profile. The actual work is narrower: What does their tech stack look like? What's the specific pain that makes them pick up the phone? Who in the organization owns that problem, and who else has to sign off? When you define that with precision, everything downstream — messaging, outbound targeting, discovery questions, objection handling — becomes dramatically more efficient.

Startups that skip this step don't just waste sales cycles. They generate misleading data. When you're selling to the wrong customers, your churn rates, expansion rates, and NPS scores tell you a distorted story about your product that can drive genuinely bad strategic decisions.

2. Founder-Led Sales That Doesn't Transfer

This one is subtle and consistently underestimated. A strong founder can sell almost anything. They carry conviction, domain authority, and a narrative authenticity that no sales hire can replicate on day one. Early traction built on founder-led sales often masks a fundamental problem: the pitch, the process, and the pricing logic live entirely in one person's head.

When the company tries to scale — when you bring in your first two AEs and hand them a deck and a quota — that tacit knowledge doesn't transfer. What looked like a repeatable sales motion was actually a charismatic exception. The new reps struggle. You assume they're underperforming. Sometimes they are. More often, they were never given a process that actually works without a founder in the room.

The fix isn't hiring better salespeople. It's doing the hard work of systematizing what the founder actually does: mapping the real buyer journey, documenting where deals stall and why, building discovery frameworks that surface the specific triggers that drive urgency. This is unglamorous work. It doesn't make for good board meeting slides. But it's the difference between a sales org that scales and one that perpetually underperforms against plan.

3. Pricing Built Around Cost, Not Value

Early-stage pricing is frequently driven by anxiety rather than analysis. Founders worry about being too expensive, so they price low enough to feel "safe." The problem is that pricing signals value, and underpricing doesn't just hurt margin — it actively attracts the wrong customers and repels the right ones.

At VoyagerMed, one of our pivotal moments was revisiting how we were pricing relative to the outcomes we were actually delivering. We weren't selling software. We were compressing critical workflows in a clinical environment where time and accuracy have measurable downstream consequences. When we reframed pricing around the value of that outcome rather than the cost of delivering it, something counterintuitive happened: the sales cycle shortened. Buyers who understood the ROI didn't need to negotiate us down to feel comfortable.

Pricing conversations are also some of the most valuable market intelligence you'll ever collect. How a prospect reacts to your price — what objections surface, which stakeholders push back — tells you exactly how they perceive your value. Founders who avoid that conversation by pricing low are throwing away one of the richest sources of GTM signal available to them.

4. No Feedback Loop Between Sales and Product

This one compounds quietly and expensively. When the objections that kill deals in Q1 never reach the product team, the same objections kill deals in Q3 — and Q4, and the year after that. There's no structural mechanism translating front-line sales intelligence into product and positioning decisions.

The fix isn't just a shared Slack channel or a monthly meeting. It requires deliberate process: capturing loss reasons with specificity, distinguishing between objections that signal a product gap versus objections that signal a messaging gap, and routing that intelligence to the right decision-makers with enough context to act on it. When this loop works, product and GTM become genuinely aligned. When it doesn't, they operate as parallel organizations solving different versions of the same problem.

What Actually Fixes This

The turnaround, in every case I've been part of, started in the same place: a willingness to narrow. Not as a permanent constraint, but as a strategic choice to go deep on a specific ICP before attempting to go broad.

At VoyagerMed, the decision to narrow our focus — to be very clear about which clinical environments we were built for, how their buying process actually worked, and what outcomes we were uniquely positioned to deliver — was the move that unlocked scalable growth. We stopped trying to be a solution for everyone and became the obvious solution for someone. The business became dramatically easier to sell, easier to retain, and ultimately more valuable to acquire.

That pattern holds across every company I've worked with since. Narrowing your ICP doesn't limit your market. It gives you a beachhead from which to expand with momentum, reference customers, and a proven motion — rather than thrashing across segments with none of the above.

• Define your ICP with operational specificity — not demographics, but decision triggers, buying dynamics, and pain severity.
• Document and stress-test your sales process before you hire into it. If it only works when the founder is in the room, it isn't a process yet.
• Price to value, not to comfort. Use pricing conversations as market intelligence, not just negotiation.
• Build a structured feedback loop between sales and product — with defined owners, regular cadence, and enough specificity to drive decisions.

The Takeaway

Before you greenlight another product sprint to fix slow growth, do the audit first. Pull your last ten lost deals and find the real reasons — not the polite ones prospects give on exit calls, but the actual friction points documented throughout the cycle. Map your sales process against how your best customers actually made their buying decision. Look at your pricing through the lens of the ROI you deliver, not the costs you're covering.

Most of the time, you won't find a product problem. You'll find a focus problem — and a GTM motion that was never truly built to scale. That's a harder conversation to have than approving another feature sprint. But it's the conversation that actually moves the number.

The founders I've seen build durable, scalable companies aren't the ones with the best products. They're the ones who got brutally honest about their go-to-market fundamentals early enough to fix them. That's the advantage that compounds.